Sanela Bilic

Subiaco, WA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges.

T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges.

Journal: Cancers

Published: September 13, 2025

A Single Arm Pilot Observational Study to Evaluate the Safety and Feasibility of a Pre-Operative Very Low Calorie Diet in Severely Obese Patients With Endometrial Cancer.

A Single Arm Pilot Observational Study to Evaluate the Safety and Feasibility of a Pre-Operative Very Low Calorie Diet in Severely Obese Patients With Endometrial Cancer.

Journal: Cancer reports (Hoboken, N.J.)

Published: August 08, 2024

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.

Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis.

Journal: Nature communications

Published: August 08, 2024

Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.

Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.

Journal: Neurology

Published: February 08, 2024

Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.

Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones.

Journal: Nature communications

Published: October 05, 2022

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.

Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.

Journal: The Journal of clinical investigation

Published: June 13, 2022

TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.

TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 09, 2022

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.

Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.

Journal: Gynecologic oncology reports

Published: September 29, 2021

Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.

Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 23, 2021

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Journal: Virchows Archiv : an international journal of pathology

Published: September 13, 2021

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors.

Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors.

Journal: International journal of toxicology

Published: March 19, 2021

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.

Journal: Advances in therapy

Published: March 15, 2021

Showing 1-12 of 26

Last Updated: 09/26/2026